Clifford Samuel is Gilead's Senior Vice President of Access Operations and Emerging Markets, with responsibility for more than 130 countries around the world. He joined Gilead Sciences in 1996 as a member of the company’s commercial organization, newly established at the time, to support the introduction of Gilead’s first commercial product.
Today Mr. Samuel oversees the ongoing development and implementation of innovative manufacturing, distribution and business models to make the company’s HIV, viral hepatitis and fungal medicines available at affordable prices in resource-limited and evolving economies. In addition to coordinating Gilead’s internal operations in these markets, Mr. Samuel builds strategic partnerships around the world, including collaborations with governments, non-governmental organizations and generic drug manufacturers to ensure that large-scale access to medicines is achieved.
Under his leadership, Gilead has entered into generic licensing agreements with 19 companies in China, India and South Africa, creating a competitive market for generic HIV and hepatitis B drugs that has dramatically reduced prices and helped to deliver medicines to more than 10 million people in need. Starting in 2014, Gilead extended licensing agreements to 11 Indian manufacturers to scale up access to hepatitis C treatments in 101 countries, including Egypt, India and Pakistan.
Mr. Samuel serves as a member of the New Jersey Institute of Technology (NJIT) Honor Program Board. He received his bachelor’s degree in mechanical engineering from NJIT, and was awarded the Edward F. Weston Medal for Professional Achievement by the school in 2010.